Literature DB >> 15713990

Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis.

Maria Notarnicola1, Caterina Messa, Aldo Cavallini, Maurizio Bifulco, Mario Felice Tecce, Davide Eletto, Alfredo Di Leo, Severino Montemurro, Chiara Laezza, Maria Gabriella Caruso.   

Abstract

OBJECTIVE: Farnesyl diphosphate synthase (FPPs) produces FPP which is considered a branch-point intermediate in the synthesis of sterols and isoprenylated cellular metabolites. In this study we investigated whether detectable FPPs activity was present in human colorectal cancer (CRC), also evaluating in vitro the role of this enzyme in the growth and apoptosis of CRC cells by using Pamidronate (PAM), a FPPs activity inhibitor.
METHODS: The activity level of FPPs was determined in CRC and the normal surrounding mucosa of 50 patients by radiochemical assay. The FPPs mRNA expression was investigated in 15 of 50 patients by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). K-ras mutation was evaluated using PCR and restriction enzyme analysis. Cell growth and apoptosis, after PAM treatment, in human CRC cell line DLD-1 were measured by MTT test and DNA fragmentation, respectively.
RESULTS: FPPs activity was detectable in human CRC. FPPs activity and its mRNA were significantly more abundant in cancer samples than in normal mucosa. In vitro PAM resulted in a significant reduction of cell growth and also gave rise to a marked proapoptotic effect.
CONCLUSIONS: This study provides the first evidence of the presence of FPPs activity in human CRC. Moreover, FPPs enzyme was found to play a significant role in colon cancer proliferation. Copyright (c) 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15713990     DOI: 10.1159/000082918

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  14 in total

1.  Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?

Authors:  Tilman Todenhöfer; Jörg Hennenlotter; Ursula Kühs; Valentina Gerber; Georgios Gakis; Ulrich Vogel; Stefan Aufderklamm; Axel Merseburger; Judith Knapp; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2012-03-11       Impact factor: 4.226

2.  An enzyme-coupled continuous fluorescence assay for farnesyl diphosphate synthases.

Authors:  Jonathan K Dozier; Mark D Distefano
Journal:  Anal Biochem       Date:  2011-10-28       Impact factor: 3.365

3.  Effect of genistein on cholesterol metabolism-related genes in a colon cancer cell line.

Authors:  Maria Notarnicola; Caterina Messa; Antonella Orlando; Benedetta D'Attoma; Valeria Tutino; Rosemary Rivizzigno; Maria Gabriella Caruso
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

4.  Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Authors:  Sarah A Holstein; Huaxiang Tong; Raymond J Hohl
Journal:  Leuk Res       Date:  2009-07-30       Impact factor: 3.156

5.  Gene expression of rat alveolar type II cells during hyperoxia exposure and early recovery.

Authors:  Zhongming Chen; Narendranath Reddy Chintagari; Yujie Guo; Manoj Bhaskaran; Jiwang Chen; Li Gao; Nili Jin; Tingting Weng; Lin Liu
Journal:  Free Radic Biol Med       Date:  2007-05-31       Impact factor: 7.376

6.  Dietary-suppression of hepatic lipogenic enzyme expression in intact male transgenic mice.

Authors:  Maria Notarnicola; Maria Gabriella Caruso; Angela Tafaro; Valeria Tutino; Giusy Bianco; Mario Minoia; Antonio Francavilla
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

7.  Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events.

Authors:  Jürgen Borlak; Prashant Singh; Giuseppe Gazzana
Journal:  BMC Genomics       Date:  2015-02-25       Impact factor: 3.969

8.  Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.

Authors:  Heidrun Karlic; Roman Thaler; Christopher Gerner; Thomas Grunt; Katharina Proestling; Florian Haider; Franz Varga
Journal:  Cancer Genet       Date:  2015-03-18

9.  Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.

Authors:  B Ory; G Moriceau; V Trichet; F Blanchard; M Berreur; F Rédini; M Rogers; D Heymann
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

Review 10.  Human isoprenoid synthase enzymes as therapeutic targets.

Authors:  Jaeok Park; Alexios N Matralis; Albert M Berghuis; Youla S Tsantrizos
Journal:  Front Chem       Date:  2014-07-22       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.